Houston-based cancer and disease bio-venture launches after $38.1M series A

money moves

A Houston biotech company has raised $38.1 million. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Sporos Bioventures LLC launched this month after closing a $38.1 million round of series A financing.

The Houston-based biotech company aims to accelerate the development of breakthrough therapies for cancer and immune diseases by sharing resources, capital, access to clinical trial infrastructure, and talent from within its knowledgeable team of biotech executives, entrepreneurs, academic scholars, and investors. The company was launched with four entities: Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, and Stellanova Therapeutics.

The most advanced of the four entities, Tvardi, is currently in Phase 1 clinical trial to evaluate it's STAT3 oral inhibitor. It was named a "most promising" life sciences company at the 2020 Texas Life Science Forum, hosted by BioHouston and the Rice Alliance in December. The remaining entities are in the development stages and are focused on cancer, autoimmune disease, fibrosis, and tumor growth, among other conditions.

"Sporos was founded to accelerate the development of new medicines by addressing inefficiencies and risk in the establishment of new biotech companies," Peter Feinberg, Sporos co-founder, said in a statement. "By leveraging our extensive network, including the Texas Medical Center, we first identify transformative scientific opportunities and then deploy our top-tier talent, funding, and operational support to drive these insights into a growing pipeline of first-in-class treatment options."

In conjunction with the launch, Sporos named Michael Wyzga as the company's founding CFO. Wyzga was previously CFO at Genzyme for 12 years and has held various senior-level positions in the industry.

"By strategically deploying valuable resources to young companies that would not typically be supported by top-tier seasoned talent and infrastructure, we believe that we can efficiently bring a diverse set of therapies through clinical development," Wyzga said in a statement. "I am thrilled to join a team with decades of scientific and operational expertise and look forward to guiding our strategic and financial growth."

Wyzga joins a team of seasoned leaders in the biotech and cancer research fields, including Dr. Ronald DePinho, professor of Cancer Biology and past president of MD Anderson, who will serve as the chair of Sporos' Strategic Advisory Council. Jeno Gyuris, a biotech executive in oncology drug discovery and development with more than 25 years of experience, will serve as chief science officer. And Alex Cranberg, an experienced active early-stage biotech investor, serves as director.

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Houston biotech startup raises millions to battle pediatric cancer

fresh funds

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."
A new tool being used at Houston Methodist taps into artificial intelligence breast cancer diagnosis. Photo courtesy of Houston Methodist

Houston hospital uses AI to create new breast cancer risk calculator

iBrisk

In the medical field, billions of dollars are wasted each year — about $935 billion, but who's counting? According to a paper published by the JAMA Network, an estimated $75.7 billion to $101.2 billion is wasted through overtreatment. Of the many procedures that can lead to wasted resources, breast cancer biopsies are a major source of overtreatment. Houston Methodist Hospital is using artificial intelligence to create a more efficient and accurate Breast Cancer Risk Calculator, called iBrisk.

Breast cancer is something that plagues the lives of many women, and some men. According to the National Breast Cancer Foundation, one in eight women will be diagnosed with breast cancer in their lifetime.

Women are advised to start having annual mammograms to screen for breast cancer starting at age 40 to try to catch cancer in its earliest stages. With mammograms becoming a standard procedure, the process inevitably leads to more biopsies.

While more biopsies sound like the obvious course of action, Houston Methodist Hospital shares that out of 10,000 women biopsied, less than two will be positive while using the national standard. The result of a negative biopsy? Wasted time, resources, and money, as well as undue worry for the patient.

"It's not just wasteful. . .when you do an unnecessary procedure, you're potentially harming the patient," says Stephen Wong, Ph.D. After a negative biopsy, Dr. Wong explains that patients often begin to show emotional responses like high anxiety and low self-esteem. They often speculate the biopsies are wrong, and that they've had a missed cancer diagnosis by their medical provider.

Dr. Wong estimates that more than 700,000 patients have unnecessary biopsies in the breast cancer category alone.

Spearheading the iBrisk tool, Dr. Wong has found a way to utilize a smarter model than the current system for detecting breast cancer risk.

Hospitals across the country currently use the Breast Imaging Reporting and Database System score (BI-RADS), a system created by the American College of Radiology to determine breast cancer risk and biopsy decision-making.

To expand on BI-RADS data, Dr. Wong used multiple patient data points and AI technology to create the improved system. The iBRISK integrates natural language processing, medical image analysis, and deep learning on multi-modal BI-RADS patient data to make one of three recommendations: biopsy not recommended, consider biopsy, or biopsy recommended.

"While using AI, we try to simulate how the physician thinks," explains Dr. Wong. "The physician looks at different data: imaging, patient clinical data, demographic, history and other social factors. You don't rely on one particular thing."

To create iBrisk, Dr. Wong used 12 to 13 years of BI-RAD data at Houston Methodist Hospital to train the AI using deep learning.

He estimates that more than 80 percent of technical information is in the free text format, meaning unstructured data, in the United States.

"We applied an AI technique called natural language processing, which is using the computer to read the text automatically for us," explains Dr. Wong.

This data extraction tool was also used with imaging of mammogram ultrasounds by applying image analysis computer vision.

iBrisk also deploys deep learning, a machine learning tactic where artificial neural networks, inspired by the human brain, learn from large amounts of data. They determined approximately 100 parameters to analyze, including age, sex, socio-economic data, medical history, and insurance plans. After putting the data points into a deep learning method, the AI reduced the data points to the 20 risk indicators.

Houston Methodist Hospital used an estimated 11,000 cases for training, and then used 2,200 of its own data to test iBrisk. They have even been able to create unbiased independent validation by working with other hospitals like MD Anderson, testing their patients using iBrisk and confirming the results.

The potential of iBrisk to cut costs and contribute to less overtreatment has garnered support with other hospitals around the country. The breast cancer risk calculator is a collaboration with Dr. Jenny Chang of HMCC and breast oncologists at MD Anderson, UT San Antonio, and University of Utah Cancer Center.

While implicit racial bias has become a more prominent issue in the United States, Houston Methodist's iBrisk grants a neutral, unbiased lens. AI isn't immune to racial bias; in fact, computer scientist and founder of the Algorithmic Justice League, Joy Buolamwini, uncovered the large gender and racial biases of AI systems sold by IBM, Amazon and Microsoft in a 2019 article for Time.

With AI's history of racial bias in mind, Dr. Wong set out to create an impartial, fair system. "Our AI data is not sensitive to race. . .it's unbiased," he explains.

Houston Methodist Hospital plans to expand the iBrisk model to other forms of cancer in the future, including its next venture into thyroid and incidental lung nodule screenings.

The AI allows patients to save the stress of getting a biopsy.

"We are very careful to put any drugs or any procedure into clinical workflow until we are very sure you really have to pick this [outcome]," explains Dr. Wong. Using advanced risk detectors like iBrisk allows medical practitioners to make more thorough, informed decisions for patients looking into biopsies.

The categories are broken into low, moderate and high-risk groups. The low-risk groups have seen a 99.8 percent accuracy in results, missing only two cases out of a sample of 1,228. Patients that have fallen into the high-risk groups (leading patients to get a biopsy) have seen an 85.9 percent accuracy, compared to radiology, which is 25 percent accurate according to Dr. Wong.

Dr. Wong notes that patients that fall in the moderate section of the risk assessment can then have a dialogue with their physician to determine if they want to move forward with the biopsy. In the moderate category, there is a 93.4 percent accuracy.

If implemented, iBrisk would be able to reduce 75 percent of unnecessary biopsies, estimates Dr. Wong.

Currently, Houston Methodist Hospital is using AI technology outside of oncology, with the recent release of a tool that can diagnose strokes using a smartphone, announced in Science Daily. The tool, which can diagnose abnormalities in a patient's speech and facial muscular movements, was made in collaboration with Dr. Jay Volpi of Eddy Scullock Stroke Center at Houston Methodist Hospital.

"We are answering bigger questions," explains Dr. Wong, who looks forward to continuing to expand AI capabilities and risk calculators at Houston Methodist Hospital.

In the future, Dr. Wong looks forward to doing a multicenter trial to bring this technology outside of Texas.

Five cancer research teams have been selected to receive funds from a new initiative from the University of Texas. Photo via news.utexas.edu

UT system funds Houston researchers in new collaboration to cure cancer

collaborate for a cure

In a renewed effort to move the needle on finding a cure for cancer, the University of Texas system has launched a new collaboration in oncological data and computational science across three programs.

Houston-based University of Texas MD Anderson Cancer Center has teamed up with two UT Austin schools — the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center. The collaboration was announced this summer to tap into mathematical modeling and advanced computing along with oncology expertise to inspire new methods of cancer treatment.

"Integrating and learning from the massive amount of largely unstructured data in cancer care and research is a formidable challenge," says David Jaffray, Ph.D., chief technology and digital officer at MD Anderson, in a news release. "We need to bring together teams that can place quantitative data in context and inform state-of-the-art computational models of the disease and accelerate progress in our mission to end cancer."

Now, the first five projects to be funded under this new initiative have been announced.

  • Angela Jarrett of the Oden Institute and Maia Rauch of MD Anderson will develop a patient-specific mathematical model for forecasting treatment response and designing optimal therapy strategies for patients with triple-negative breast cancer.
  • Caroline Chung of MD Anderson and David Hormuth of the Oden Institute are using computational models of the underlying biology to fundamentally change how radiotherapy and chemotherapy are personalized to improve survival rates for brain cancer patients.
  • Ken-Pin Hwang of MD Anderson and Jon Tamir of UT Austin's Department of Electrical and Computer Engineering and the Oden Institute will use mathematical modeling and massively parallel distributed computing to make prostate MR imaging faster and more accurate to reduce the incidence of unnecessary or inaccurate biopsies.
  • Xiaodong Zhang of MD Anderson and Hang Liu of TACC will advance both the planning and delivery of proton therapy via a platform that combines mathematical algorithms and high-performance computing to further personalize these already highly tailored treatments.
  • Tinsley Oden and Prashant Jha of the Oden Institute and David Fuentes of MD Anderson will integrate a new mechanistic model of tumor growth with an advanced form of MRI to reveal underlying metabolic alterations in tumors and lead to new treatments for patients.

"These five research teams, made up of a cross section of expertise from all three stakeholders, represent the beginning of something truly special," says Jaffray in a release. "Our experts are advancing cancer research and care, and we are committed to working with our colleagues at the Oden Institute and TACC to bring together their computational expertise with our data and insights."

Later this month, the five teams will log on to a virtual retreat along with academic and government thought leaders to further collaborate and intertwine their research and expertise.

"Texas is globally recognized for its excellence in computing and in cancer research. This collaboration forges a new path to international leadership through the combination of its strengths in both," says Karen Willcox, director of the Oden Institute. "We are thrilled that leaders in government, industry and academia see the potential of this unique Texan partnership. We're looking forward to a virtual retreat on October 29 to continue to build upon this realization."
Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.
Breakthrough research on metastatic breast cancer, a new way to turn toxic pollutants into valuable chemicals, and an evolved brain tumor chip are three cancer-fighting treatments coming out of Houston. Getty Inages

These 3 Houston research projects are aiming to fight or prevent cancer

Research roundup

Cancer remains to be one of the medical research community's huge focuses and challenges, and scientists in Houston are continuing to innovate new treatments and technologies to make an impact on cancer and its ripple effect.

Three research projects coming out of Houston institutions are providing solutions in the fight against cancer — from ways to monitor treatment to eliminating cancer-causing chemicals in the first place.

Baylor College of Medicine's breakthrough in breast cancer

Photo via bcm.edu

Researchers at Baylor College of Medicine and Harvard Medical School have unveiled a mechanism explains how "endocrine-resistant breast cancer acquires metastatic behavior," according to a news release from BCM. This research can be game changing for introducing new therapeutic strategies.

The study was published in the Proceedings of the National Academy of Sciences and shows that hyperactive FOXA1 signaling — previously reported in endocrine-resistant metastatic breast cancer — can trigger genome-wide reprogramming that enhances resistance to treatment.

"Working with breast cancer cell lines in the laboratory, we discovered that FOXA1 reprograms endocrine therapy-resistant breast cancer cells by turning on certain genes that were turned off before and turning off other genes," says Dr. Xiaoyong Fu, assistant professor of molecular and cellular biology and part of the Lester and Sue Smith Breast Center at Baylor, in the release.

"The new gene expression program mimics an early embryonic developmental program that endow cancer cells with new capabilities, such as being able to migrate to other tissues and invade them aggressively, hallmarks of metastatic behavior."

Patients whose cancer is considered metastatic — even ones that initially responded to treatment — tend to relapse and die due to the cancer's resistance to treatment. This research will allow for new conversations around therapeutic treatment that could work to eliminate metastatic cancer.

University of Houston's evolved brain cancer chip

Photo via uh.edu

A biomedical research team at the University of Houston has made improvements on its microfluidic brain cancer chip. The Akay Lab's new chip "allows multiple-simultaneous drug administration, and a massive parallel testing of drug response for patients with glioblastoma," according to a UH news release. GBM is the most common malignant brain tumor and makes up half of all cases. Patients with GBM have a five-year survival rate of only 5.6 percent.

"The new chip generates tumor spheroids, or clusters, and provides large-scale assessments on the response of these GBM tumor cells to various concentrations and combinations of drugs. This platform could optimize the use of rare tumor samples derived from GBM patients to provide valuable insight on the tumor growth and responses to drug therapies," says Metin Akay, John S. Dunn Endowed Chair Professor of Biomedical Engineering and department chair, in the release.

Akay's team published a paper in the inaugural issue of the IEEE Engineering in Medicine & Biology Society's Open Journal of Engineering in Medicine and Biology. The report explains how the technology is able to quickly assess how well a cancer drug is improving its patients' health.

"When we can tell the doctor that the patient needs a combination of drugs and the exact proportion of each, this is precision medicine," Akay explains in the release.

Rice University's pollution transformation technology

Photo via rice.edu

Rice University engineers have developed a way to get rid of cancer-causing pollutants in water and transform them into valuable chemicals. A team lead by Michael Wong and Thomas Senftle has created this new catalyst that turns nitrate into ammonia. The study was published in the journal ACS Catalysis.

"Agricultural fertilizer runoff is contaminating ground and surface water, which causes ecological effects such as algae blooms as well as significant adverse effects for humans, including cancer, hypertension and developmental issues in babies," says Wong, professor and chair of the Department of Chemical and Biomolecular Engineering in Rice's Brown School of Engineering, in a news release. "I've been very curious about nitrogen chemistry, especially if I can design materials that clean water of nitrogen compounds like nitrites and nitrates."

The ability to transform these chemicals into ammonia is crucial because ammonia-based fertilizers are used for global food supplies and the traditional method of creating ammonia is energy intensive. Not only does this process eliminate that energy usage, but it's ridding the contaminated water of toxic chemicals.

"I'm excited about removing nitrite, forming ammonia and hydrazine, as well as the chemistry that we figured out about how all this happens," Wong says in the release. "The most important takeaway is that we learned how to clean water in a simpler way and created chemicals that are more valuable than the waste stream."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston SaaS startup raises $10M to keep up with customer growth

money moves

A Houston software company has announced its latest funding.

Liongard, an IT software provider, has raised an additional $10 million led by Updata Partners with contribution from TDF Ventures — both existing investors in the company. The funding, according to a news release, will go toward providing the best customer service for Liongard's growing customer base.

The technology is providing managed service providers, or MSPs, improved visibility across the IT stack and an optimized user experience.

“Since working with our first MSP partners, we’ve seen time and again the power of visibility into IT data, reducing the time they spend researching customer issues and allowing them to respond faster than their peers,” says Joe Alapat, CEO and co-founder of Liongard, in the release. “This investment enables us to continue to achieve our vision of delivering visibility into each element of the IT stack.”

The company has about 2,000 partners in support of more than 60,000 end customers. And has been recognized as a top employer by Forbes and Inc. magazine earlier this year.

“We are excited to deepen our commitment with Liongard,“ says Carter Griffin, general partner at Updata, in the release. “With its leading data platform for MSPs we expect continued fast-paced growth.”

Liongard's last funding round was in May of 2020 and was a $17 million series B round. Both Updata Partners and TDF ventures were involved in that round. The company's total funding now sits at over $30 million.

Rice University rises to No. 1 spot in new ranking of best college investments

money moves

By one measure, earning a degree at Rice University is the smartest move in the Lone Star State.

In its eighth annual ranking of colleges and university that give students the best return on their educational investment, personal finance website SmartAsset places Rice at No. 1 in Texas and No. 10 in the U.S. It’s the only Texas school to break into the national top 10.

To determine the best-value colleges and universities in each state, SmartAsset crunched data in these categories: scholarships and grants, starting salary for new graduates, tuition, living costs, and retention rate.

While the tuition ($47,350) and student living costs ($17,800) at Rice are the highest among the top 10 Texas schools on the list, the average amount of scholarships and grants ($43,615), average starting salary ($77,900), and retention rate (97 percent) also are among the highest.

According to Rice, tuition, fees, on-campus room and board, books, and personal expenses for the 2022-23 academic year add up to $74,110. That figure, which excludes financial aid, applies to a full-time, degree-seeking student living on campus.

“Rice University is consistently ranked as a best value in higher education and is one of America’s leading teaching and research universities,” the school’s Office of Financial Aid says. “By attending Rice, you will not only receive a superior education at a reasonable cost, you also will benefit from having a Rice degree long after graduation.”

Three other schools in or near the Houston metro area appear on SmartAsset’s list of the biggest-bang-for-your-buck schools in Texas:

  • Prairie View A&M University, No. 4. The university posted the lowest retention rate (74 percent) among the 10 schools. The remaining figures sit roughly in the middle of the pack.
  • University of Houston, No. 5. The university’s tuition ($8,913) was the lowest in the top 10, as was the average amount of scholarships and grants ($6,544).
  • Texas A&M University-College Station, No. 6. The university’s living costs are the second highest among the top 10 ($17,636), while its average starting salary for new grads lands at No. 3 ($64,400).

Other schools in the state’s top 10 are:

  • University of Texas at Austin, No. 2.
  • University of Texas at Dallas (Richardson), No. 3.
  • Texas Tech University in Lubbock, No. 7.
  • LeTourneau University in Longview, No. 8.
  • University of North Texas in Denton, No. 9.
  • Texas State University in San Marcos, No. 10.

------

This article originally ran on CultureMap.

Houston expert addresses the growing labor shortage within health care

guest column

Long before COVID-19 became a part of our new normal, the concerns around shortages in health care staffing were present.

To put this in real terms, according to the Bureau of Labor Statistics, the latest projection of employment through the end of this decade is an increase of nearly 12 million jobs. A fourth of those — 3.3 million to be exact — are expected to go towards health care and social assistance roles.

Before the pandemic, the concerns centered around managing a growing retired population and a slowing in higher education nurse enrollment. Then amid the growing shortage concerns surrounding the support for aging baby boomers, we were all thrusted into a pandemic.

The stressors on health care professional staffing have doubled down and what the increased shortage has shown us is the need to intervene and change the traditional hiring practices. Speed to place a nurse on assignment doesn’t just ensure productivity — it is a matter of life or death.

Over the past several years, the evolution of technology has drastically changed how health care facilities operate and interact with their employees as well as patients. There was a point in time where the structure in health care staffing was rigid without flexibility or varieties of employment type. Conversations around travel positions, per diem, and permanent are all now commonplace as the recent shortages caused us to normalize the discussion around role type and use of technology to influence speed to hire.

This whole evolution was put to test when April 2020 came, and the initial brunt of the pandemic was in full swing. The entire world was in panic mode. During these quarantine times, we were in a state of a health care emergency with thousands of patients seeking health care. Unfortunately, hospitals could not keep up with this demand with their existing nurse professionals, and became severely overloaded and dangerous. Due to this the United States saw unprecedented labor shortages, impacting a large number of nurses and health care workers as it pertains to both their physical and mental health.

What we are seeing now is a period classified as the “The Great Rethinking,” where nurses and health care workers alike are speaking up for what they believe in and deserve. Salary transparency and flexibility are just the tip of the iceberg for this movement.

SkillGigs is unique in that we are giving the power back to registered nurses and health care professionals, while meeting the demand created by the pandemic. Our team has been fortunate to be a catalyst to direct the change in the future of work, and we look forward to continuing to innovate.

------

Bryan Groom is the division president of health care at Houston-based SkillGigs.

View All Listings